SC Therapeutics Launches REACH2 Clinical Trial to Evaluate Novel Disease-Modifying Therapy for Refractory Chronic Cough
SC Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies that target mechano-sensitive ion channels (MSCs) for the treatment of respiratory and cardiovascular diseases, has announced the initiation of its Phase REACH2 clinical trial. The study will evaluate the company’s lead investigational therapy, SC0032, in patients suffering from refractory chronic cough (RCC), a condition that significantly impacts quality of life and currently lacks disease-modifying treatment options.
The REACH2 trial represents an important milestone in the company’s clinical development strategy and builds upon findings from its earlier REACH1 study. Conducted across three leading specialist cough centers in the United Kingdom, the trial is designed not only to assess the treatment’s effectiveness in reducing chronic cough but also to investigate whether its therapeutic benefits continue after treatment has ended—an outcome that could distinguish SC0032 from currently available investigational therapies.
Addressing a Significant Unmet Medical Need
Refractory chronic cough is a persistent cough that continues despite appropriate treatment of any underlying medical conditions. Patients often experience coughing for months or even years, with symptoms that interfere with daily activities, sleep, social interactions, and overall well-being.
The condition can be physically exhausting, leading to complications such as chest pain, urinary incontinence, voice disturbances, sleep disruption, fatigue, and psychological distress. Many patients report significant reductions in their quality of life due to the constant nature of their symptoms.
Although several investigational treatments have focused on reducing cough frequency by suppressing nerve signaling, no approved therapy currently addresses the underlying biological mechanisms responsible for chronic cough hypersensitivity in a disease-modifying manner.
SC Therapeutics aims to change that paradigm through a fundamentally different therapeutic strategy.
A Novel Therapeutic Approach
The company’s lead product candidate, SC0032, is a proprietary inhaled aerosol therapy composed entirely of ions that are naturally present within the human airways.
Unlike traditional pharmaceutical agents that rely on synthetic molecules, SC0032 utilizes endogenous ions designed to restore normal physiological function within the respiratory tract.
According to SC Therapeutics, the therapy targets mechano-sensitive ion channels, or MSCs, which play an important role in sensing mechanical forces within airway tissues.
Increasing scientific evidence suggests that abnormal activation of these channels contributes to chronic cough hypersensitivity by promoting inflammation and excessive cough reflex sensitivity.
Rather than suppressing cough after it occurs, SC0032 is intended to normalize the underlying biological processes that trigger chronic coughing.
Differentiating from Existing Investigational Therapies
Most investigational therapies currently being developed for refractory chronic cough work by blocking receptors involved in transmitting cough signals.
Among the leading approaches are:
- P2X3 receptor antagonists, which reduce nerve signaling associated with chronic cough.
- Neurokinin-1 (NK1) receptor antagonists, which also target pathways involved in cough reflex activation.
While these therapies aim to reduce symptoms by dampening neural hypersensitivity, they primarily act downstream in the disease process.
SC0032 employs a different mechanism by targeting upstream inflammatory processes believed to contribute to persistent cough hypersensitivity.
The company believes that relieving compression and abnormal activation of mechano-sensitive ion channels may address one of the root causes of chronic cough rather than simply suppressing its symptoms.
Potential for Disease Modification
One of the most notable aspects of SC0032 is its potential to produce lasting therapeutic benefits beyond the active treatment period.
Because the therapy is designed to normalize dysfunctional airway biology instead of temporarily blocking cough signaling, investigators believe improvements may continue even after dosing has stopped.
Such sustained benefit would represent a disease-modifying effect rather than temporary symptom relief.
This possibility forms one of the central scientific hypotheses being evaluated in the REACH2 clinical study.
If demonstrated, durable treatment effects could differentiate SC0032 from existing symptomatic treatment strategies and potentially establish a new therapeutic category for refractory chronic cough.
REACH2 Trial Design
The REACH2 study has been designed as a randomized, placebo-controlled clinical trial.
Patients enrolled in the study will receive treatment over a three-week dosing period.
Following completion of treatment, participants will enter a four-week follow-up phase during which no study medication will be administered.
This extended observation period is intended to determine whether improvements in cough persist after therapy has ended.
The inclusion of a post-treatment assessment reflects the company’s emphasis on evaluating disease modification rather than solely measuring symptom suppression during active treatment.
Objective Measurement of Cough
Accurately measuring chronic cough presents a significant challenge for clinical research.
Cough frequency often varies considerably from one day to another, making it difficult to distinguish natural fluctuations from genuine treatment effects.
To improve the reliability of efficacy assessments, the REACH2 study will utilize Hyfe’s CoughMonitor Suite, a digital monitoring platform capable of continuously recording and objectively counting cough events.
Continuous monitoring allows researchers to collect comprehensive cough data throughout the study rather than relying solely on patient diaries or intermittent assessments.
This technology is expected to provide more precise and reproducible measurements of treatment response.
Addressing Day-to-Day Variability
Recognizing the inherent variability of chronic cough, investigators have incorporated a robust efficacy assessment strategy into the trial design.
Rather than comparing isolated measurements, the primary efficacy endpoint will analyze seven consecutive days of objective cough monitoring during the baseline period against seven consecutive days collected at the conclusion of treatment.
By averaging cough frequency across entire weeks, researchers hope to minimize the influence of daily fluctuations and generate a more accurate estimate of treatment benefit.
The company believes this extended monitoring approach will strengthen the statistical reliability of study outcomes and improve interpretation of the clinical results.
Conducting the Study at Specialized Centers
The REACH2 trial is being conducted at three major specialist respiratory centers in the United Kingdom.
Participating institutions include:
- Royal Brompton Hospital
- King’s College Hospital
- Belfast City Hospital
These internationally recognized centers possess extensive expertise in the diagnosis and management of chronic cough and are expected to provide high-quality clinical oversight throughout the study.
Their involvement also supports enrollment of patients with well-characterized refractory chronic cough, ensuring rigorous evaluation of the investigational therapy.
Building on Earlier Clinical Findings
The REACH2 study follows encouraging observations from the earlier REACH1 trial.
According to SC Therapeutics, preliminary findings suggested that treatment with SC0032 was associated with rapid reductions in both cough frequency and cough bouts.
Researchers also observed indications that cough hypersensitivity itself may decrease more gradually over time.
This pattern is consistent with the proposed mechanism of action, in which normalization of mechano-sensitive ion channel activity may require sustained biological adaptation before full therapeutic effects become apparent.
The REACH2 study has therefore been designed to further investigate these observations under controlled conditions.
Leadership Highlights Broader Potential
David A. Edwards, scientific founder and Chief Executive Officer of SC Therapeutics, expressed enthusiasm regarding the launch of the REACH2 trial.
He noted that the study provides an opportunity to clarify findings from REACH1 while further evaluating both the rapid reduction in cough frequency and the longer-term improvements in cough hypersensitivity that the company believes may result from down-regulation of mechano-sensitive ion channels.
Dr. Edwards also emphasized that insights gained from SC0032 may extend beyond refractory chronic cough.
Because dehydrated airway mucosa and abnormal mechano-sensitive ion channel activity have been implicated in numerous respiratory and cardiovascular disorders, understanding the effects of SC0032 could help guide future therapeutic development across a broader range of diseases.
The initiation of the REACH2 trial marks another important step in SC Therapeutics’ efforts to develop innovative treatments for chronic respiratory disease.
By targeting the underlying biological mechanisms believed to drive chronic cough rather than merely suppressing symptoms, SC0032 has the potential to represent a fundamentally different therapeutic approach.
If the study demonstrates sustained clinical benefits following treatment, it could provide early evidence supporting the concept of disease modification in refractory chronic cough—a significant advancement for a patient population that currently has limited therapeutic options.
As recruitment progresses and data become available, the findings from REACH2 are expected to contribute valuable insights into both the biology of chronic cough and the future role of mechano-sensitive ion channel modulation in respiratory medicine.
About Refractory Chronic Cough
Refractory chronic cough affects millions of patients worldwide who fail to achieve adequate relief with standard treatments. The condition is characterized by cough hypersensitivity – in which the cough reflex threshold is pathologically lowered – resulting in persistent, often disabling cough that significantly impairs quality of life. Despite growing recognition of the disease burden, approved therapies remain limited and none have demonstrated disease-modifying properties. Mechano-sensitive ion channels have emerged as a promising therapeutic target given their role in transducing mechanical stimuli to drive the hypersensitive cough reflex.
About SC Therapeutics
SC Therapeutics,formerly Sensory Cloud Inc,is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies that deactivate mechano-sensitive ion channels implicated in respiratory and cardiovascular disease. The Company’s proprietary platform leverages the biology of endogenous airway ions to modulate MSC activity, with the goal of achieving disease-modifying outcomes across conditions driven by aberrant mechanical signaling. SC Therapeutics is headquartered in Boston, Massachusetts.
